Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Expression of CCCTC-binding factor (CTCF) is linked to poor prognosis in prostate cancer.
Höflmayer D, Steinhoff A, Hube-Magg C, Kluth M, Simon R, Burandt E, Tsourlakis MC, Minner S, Sauter G, Büscheck F, Wilczak W, Steurer S, Huland H, Graefen M, Haese A, Heinzer H, Schlomm T, Jacobsen F, Hinsch A, Poos AM, Oswald M, Rippe K, König R, Schroeder C. Höflmayer D, et al. Among authors: schroeder c. Mol Oncol. 2020 Jan;14(1):129-138. doi: 10.1002/1878-0261.12597. Epub 2019 Nov 29. Mol Oncol. 2020. PMID: 31736271 Free PMC article.
Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer.
Jacobsen F, Kraft J, Schroeder C, Hube-Magg C, Kluth M, Lang DS, Simon R, Sauter G, Izbicki JR, Clauditz TS, Luebke AM, Hinsch A, Wilczak W, Wittmer C, Büscheck F, Höflmayer D, Minner S, Tsourlakis MC, Huland H, Graefen M, Budäus L, Thederan I, Salomon G, Schlomm T, Melling N. Jacobsen F, et al. Among authors: schroeder c. Neoplasia. 2017 Sep;19(9):707-715. doi: 10.1016/j.neo.2017.06.003. Epub 2017 Aug 19. Neoplasia. 2017. PMID: 28830008 Free PMC article.
FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy.
Tsourlakis MC, Eleftheriadou A, Stender A, Weigand P, Grupp K, Hube-Magg C, Kluth M, Schroeder C, Steurer S, Hinsch A, Luebke A, Angerer A, Wittmer C, Friedrich E, Göbel C, Büscheck F, Heinzer H, Graefen M, Simon R, Sauter G, Wilczak W, Minner S, Schlomm T, Jacobsen F. Tsourlakis MC, et al. Among authors: schroeder c. Carcinogenesis. 2017 Dec 7;38(12):1180-1187. doi: 10.1093/carcin/bgx105. Carcinogenesis. 2017. PMID: 29029032
Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer.
Hinsch A, Brolund M, Hube-Magg C, Kluth M, Simon R, Möller-Koop C, Sauter G, Steurer S, Luebke A, Angerer A, Wittmer C, Neubauer E, Göbel C, Büscheck F, Minner S, Wilczak W, Schlomm T, Jacobsen F, Clauditz TS, Krech T, Tsourlakis MC, Schroeder C. Hinsch A, et al. Among authors: schroeder c. World J Urol. 2018 Jun;36(6):877-882. doi: 10.1007/s00345-018-2225-7. Epub 2018 Feb 9. World J Urol. 2018. PMID: 29427004
PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer.
Heinrich MC, Göbel C, Kluth M, Bernreuther C, Sauer C, Schroeder C, Möller-Koop C, Hube-Magg C, Lebok P, Burandt E, Sauter G, Simon R, Huland H, Graefen M, Heinzer H, Schlomm T, Heumann A. Heinrich MC, et al. Among authors: schroeder c. BMC Cancer. 2018 May 31;18(1):612. doi: 10.1186/s12885-018-4547-7. BMC Cancer. 2018. PMID: 29855276 Free PMC article.
Loss of CCAAT-enhancer-binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers.
Minner S, Lutz J, Hube-Magg C, Kluth M, Simon R, Höflmayer D, Burandt E, Tsourlakis MC, Sauter G, Büscheck F, Wilczak W, Steurer S, Schlomm T, Huland H, Graefen M, Haese A, Heinzer H, Jacobsen F, Hinsch A, Poos A, Oswald M, Rippe K, König R, Schroeder C. Minner S, et al. Among authors: schroeder c. Prostate. 2019 Feb;79(3):302-311. doi: 10.1002/pros.23736. Epub 2018 Nov 14. Prostate. 2019. PMID: 30430607
High RSF1 protein expression is an independent prognostic feature in prostate cancer.
Höflmayer D, Hamuda M, Schroeder C, Hube-Magg C, Simon R, Göbel C, Hinsch A, Weidemann S, Möller K, Izbicki JR, Jacobsen F, Mandelkow T, Blessin NC, Lutz F, Viehweger F, Sauter G, Burandt E, Lebok P, Lennartz M, Fraune C, Minner S, Bonk S, Huland H, Graefen M, Schlomm T, Büscheck F. Höflmayer D, et al. Among authors: schroeder c. Acta Oncol. 2020 Mar;59(3):268-273. doi: 10.1080/0284186X.2019.1686537. Epub 2019 Nov 5. Acta Oncol. 2020. PMID: 31687881
Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion.
Fraune C, Harms L, Büscheck F, Höflmayer D, Tsourlakis MC, Clauditz TS, Simon R, Möller K, Luebke AM, Möller-Koop C, Steurer S, Hube-Magg C, Sauter G, Weidemann S, Lebok P, Dum D, Kind S, Minner S, Izbicki JR, Schlomm T, Huland H, Heinzer H, Burandt E, Haese A, Graefen M, Schroeder C. Fraune C, et al. Among authors: schroeder c. Mol Med. 2020 Mar 6;26(1):24. doi: 10.1186/s10020-020-00148-4. Mol Med. 2020. PMID: 32143573 Free PMC article.
Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusion-positive prostate cancers.
Luebke AM, Ricken W, Kluth M, Hube-Magg C, Schroeder C, Büscheck F, Möller K, Dum D, Höflmayer D, Weidemann S, Fraune C, Hinsch A, Wittmer C, Schlomm T, Huland H, Heinzer H, Graefen M, Haese A, Minner S, Simon R, Sauter G, Wilczak W, Meiners J. Luebke AM, et al. Among authors: schroeder c. Int J Cancer. 2020 Jul 15;147(2):575-583. doi: 10.1002/ijc.32957. Epub 2020 Mar 18. Int J Cancer. 2020. PMID: 32150281 Free article.
1,198 results